Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project.
Thomas Bardol, Antoine M Dujon, Valerie Taly...
https://pubmed.ncbi.nlm.nih.gov/38853244Actively Recruiting
Age: 18Years +
All Genders
ID05824403
Pancreatic Disease Cohort of Toulouse
Led by University Hospital, Toulouse · Updated on 2023-12-04
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a prospective cohort study focused on pancreatic diseases excluding cancer. The study aims to develop better diagnostic tools to differentiate between benign, potentially malignant, or malignant pancreatic conditions. It addresses pancreatic pathologies such as solid or cystic tumors, acute and chronic pancreatitis, and the risks of malignancy during their progression. The goal is to improve patient management by enhancing diagnosis and monitoring methods. Participants with inflammatory or cystic exocrine pancreatic diseases will be observed, with investigators collecting clinical data and biological samples over time. This observational study does not involve treatments but focuses on gathering information to support research projects. The study is led by the University Hospital in Toulouse and began in November 2023. During the study, participants will undergo specific investigations or management procedures as part of their diagnosis or treatment. Researchers will analyze diagnostic tools, new targets for disease understanding, management improvements, microbiota, and clinical data access three years after the first inclusion. Participants' data and samples will be monitored and collected throughout the study period ending in December 2027.
CONDITIONS
Brief Title
PAncreatic Disease Cohort of TOuLouse
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Patients with inflammatory or cystic exocrine pancreatic pathology
- Ability to read and understand the information leaflet
- Signed free and informed consent to participate
- Affiliated to a social security system (including AME)
You will not qualify if you...
- Patients with pancreatic cancer pathology
- Patients with active cancer of any origin
- Pregnant or breastfeeding patients
- Patients under legal protection, guardianship, or trusteeship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Diagnostic Evaluation
Duration - Up to 3 years
Participants undergo specific investigations to diagnose or manage pancreatic pathology.
Long-term Monitoring
Duration - Up to 3 years
Participants are monitored over time to improve diagnostic tools and management of pancreatic diseases.
Trial Site Locations
Total: 1 location
1
Rangueil hospital
Toulouse, France
Actively Recruiting
Loading map...
Research Team
B
Barbara BOURNET, MD
C
Cindy CANIVET
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here